U.S. Stem Cell, Inc.
USRM evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for USRM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$64K
Cash Runway
—
Lead Asset
adipocell (Phase 1)
Next Catalyst
—
Financial data as of Dec 31, 2022.
Tracking 2 pipeline candidates · 8 clinical trials for U.S. Stem Cell, Inc..
Run U.S. Stem Cell, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available U.S. Stem Cell, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
N/A
Lead: Phase 3
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Frequently asked questions
What is U.S. Stem Cell, Inc.'s lead drug candidate?
U.S. Stem Cell, Inc.'s most advanced tracked candidate is adipocell (Phase 1) for Acute myocardial infarction, chronic heart ischemia, and lower limb ischemia.
Who is the CEO of U.S. Stem Cell, Inc.?
Mr. Michael Tomas is the chief executive officer of U.S. Stem Cell, Inc. (USRM).
Where is U.S. Stem Cell, Inc. headquartered?
U.S. Stem Cell, Inc. (USRM) is headquartered in Sunrise, FL, United States.
What therapeutic areas does U.S. Stem Cell, Inc. focus on?
U.S. Stem Cell, Inc. develops therapies across Oncology, Neurology, Ophthalmology, Cardiovascular, Infectious Disease, Pain, Dermatology, Musculoskeletal, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.